The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Content within the patient forum is user-generated and has not been reviewed by medical professionals. Other sections of the Melanoma Research Foundation website include information that has been reviewed by medical professionals as appropriate. All medical decisions should be made in consultation with your doctor or other qualified medical professional.

Anni

Topics Engaged In

Viewing 7 topics - 1 through 7 (of 7 total)

- TOPIC
- ASCO 2021 – Leptomemingeal Disease
  Started by: Bubbles General Melanoma Community
- 2
- 3
- Anni
  
  2 years, 11 months ago
- Advice on genomic testing and TIL
  Started by: Anni General Melanoma Community
- 2
- 2
- Anni
  
  4 years, 1 month ago
- nivolumab and ipilimumab Skin rash
  Started by: Anni General Melanoma Community
- 5
- 9
- Anni
  
  5 years ago
- Seizures post immunotherapy ipilimumab and nivolumab
  Started by: Anni General Melanoma Community
- 2
- 3
- MelMel
  
  5 years, 1 month ago
- Intermittent dosing of dabrafenib (tafinlar) and trametinib (mekinist)
  Started by: Anni General Melanoma Community
- 5
- 6
- Christee
  
  5 years, 11 months ago
- Dabrafenib and Trametinib
  Started by: Anni General Melanoma Community
- 3
- 4
- Anni
  
  6 years, 3 months ago

Viewing 7 topics - 1 through 7 (of 7 total)

The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.